Fezagepras (sodium)

Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras sodium decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].

Product Specifications

CAS Number

[1254472-97-3]

Product Name Alternative

Setogepram (sodium) ; PBI-4050 (sodium)

UNSPSC

12352005

Hazard Statement

H315, H319, H373

Target

Free Fatty Acid Receptor; GPR84

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/PBI-4050.html

Purity

99.78

Solubility

DMSO : ≥ 64 mg/mL|H2O : ≥ 100 mg/mL

Smiles

O=C(O[Na])CC1=CC(CCCCC)=CC=C1

Molecular Formula

C13H17NaO2

Molecular Weight

228.26

Precautions

H315, H319, H373

References & Citations

[1]Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3 (10) . pii: 120365.|[2]Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367 (1) :71-81.